AU2015360095B2 - Quinoline derivative against non-small cell lung cancer - Google Patents

Quinoline derivative against non-small cell lung cancer Download PDF

Info

Publication number
AU2015360095B2
AU2015360095B2 AU2015360095A AU2015360095A AU2015360095B2 AU 2015360095 B2 AU2015360095 B2 AU 2015360095B2 AU 2015360095 A AU2015360095 A AU 2015360095A AU 2015360095 A AU2015360095 A AU 2015360095A AU 2015360095 B2 AU2015360095 B2 AU 2015360095B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
small cell
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015360095A
Other languages
English (en)
Other versions
AU2015360095A1 (en
Inventor
Yadong MIAO
Wei Shi
Shanchun WANG
Xunqiang WANG
Ling Yang
Min Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advenchen Laboratories Nanjing Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Advenchen Laboratories Nanjing Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advenchen Laboratories Nanjing Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Advenchen Laboratories Nanjing Ltd
Publication of AU2015360095A1 publication Critical patent/AU2015360095A1/en
Application granted granted Critical
Publication of AU2015360095B2 publication Critical patent/AU2015360095B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
AU2015360095A 2014-12-09 2015-12-09 Quinoline derivative against non-small cell lung cancer Active AU2015360095B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410749394.0 2014-12-09
CN201410749394 2014-12-09
PCT/CN2015/096777 WO2016091168A1 (zh) 2014-12-09 2015-12-09 抗非小细胞肺癌的喹啉衍生物

Publications (2)

Publication Number Publication Date
AU2015360095A1 AU2015360095A1 (en) 2017-07-27
AU2015360095B2 true AU2015360095B2 (en) 2020-02-27

Family

ID=56106719

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015360095A Active AU2015360095B2 (en) 2014-12-09 2015-12-09 Quinoline derivative against non-small cell lung cancer

Country Status (7)

Country Link
US (2) US10307412B2 (enExample)
EP (1) EP3231797B1 (enExample)
JP (1) JP6865684B2 (enExample)
CN (1) CN107001326B (enExample)
AU (1) AU2015360095B2 (enExample)
ES (1) ES2793286T3 (enExample)
WO (1) WO2016091168A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
CN105311030B (zh) * 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
US10307412B2 (en) 2014-12-09 2019-06-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative against non-small cell lung cancer
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
CN110078730B (zh) 2015-07-11 2021-09-07 南京爱德程医药科技有限公司 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
EP4279138A3 (en) 2018-03-02 2024-03-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of compound as c-met kinase inhibitor and preparation method therefor and use thereof
CN116440134A (zh) * 2018-05-22 2023-07-18 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的喹啉衍生物
AU2019305857B2 (en) * 2018-07-18 2025-07-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug combination of quinoline derivative and antibody
CN112638385B (zh) * 2018-09-18 2023-03-31 正大天晴药业集团股份有限公司 用于治疗脑肿瘤的喹啉衍生物
CA3112946A1 (en) * 2018-09-18 2020-03-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative used for treating small cell lung cancer
KR20210151806A (ko) * 2019-03-07 2021-12-14 어드밴첸 파마수티컬스, 엘엘씨 암 치료를 위해 순차적으로 카테켄티닙 (안로티닙)과 표준 화학요법 또는 면역요법을 조합하여 사용
EP3939610A4 (en) * 2019-03-15 2023-01-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. COMBINED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SMALL CELL LUNG CANCER
CN112274511B (zh) * 2019-07-22 2024-04-02 正大天晴药业集团股份有限公司 用于治疗移植物抗宿主病的喹啉衍生物
EP4034102A1 (en) * 2019-09-25 2022-08-03 Debiopharm International SA Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
WO2021104319A1 (zh) * 2019-11-25 2021-06-03 正大天晴药业集团股份有限公司 喹唑啉衍生物或其盐的联用药物组合物及其用途
CN120154618B (zh) * 2025-05-15 2025-11-18 正大天晴药业集团股份有限公司 格索雷塞用于治疗肺癌的用途或其药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102344438A (zh) * 2010-08-01 2012-02-08 江苏正大天晴药业股份有限公司 喹啉衍生物的结晶及其制备方法
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN101616672A (zh) 2007-02-20 2009-12-30 诺瓦提斯公司 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
EP2303890A4 (en) 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
IT1393351B1 (it) 2009-03-16 2012-04-20 Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi
JP6031118B2 (ja) * 2011-11-14 2016-11-24 ケンタウルス バイオファーマ カンパニー リミテッド キナーゼを調節する化合物、それらを含む組成物及びその用途
RU2015127211A (ru) 2013-01-18 2017-03-03 Адвенчен Фармасьютикалс, Ллс Способ получения противоопухолевого агента 6-(7-((1-аминоциклопропил) метокси)-6-метоксихинолин-4-илокси)-n-метил-1-нафтамида и его кристаллической структуры
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) * 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
ES2714100T3 (es) 2014-07-14 2019-05-27 Advenchen Pharmaceuticals Nanjing Ltd Compuestos de quinolina fusionados como inhibidores de mTor, pi3k
US10307412B2 (en) 2014-12-09 2019-06-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative against non-small cell lung cancer
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
CN110078730B (zh) 2015-07-11 2021-09-07 南京爱德程医药科技有限公司 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148532B2 (en) * 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
CN102344438A (zh) * 2010-08-01 2012-02-08 江苏正大天晴药业股份有限公司 喹啉衍生物的结晶及其制备方法

Also Published As

Publication number Publication date
AU2015360095A1 (en) 2017-07-27
US10307412B2 (en) 2019-06-04
CN107001326B (zh) 2020-05-05
CN107001326A (zh) 2017-08-01
WO2016091168A1 (zh) 2016-06-16
EP3231797A1 (en) 2017-10-18
US10888559B2 (en) 2021-01-12
EP3231797A4 (en) 2018-05-09
US20190298712A1 (en) 2019-10-03
ES2793286T3 (es) 2020-11-13
EP3231797B1 (en) 2020-02-26
JP2017537126A (ja) 2017-12-14
JP6865684B2 (ja) 2021-04-28
US20170304290A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
US10888559B2 (en) Quinoline derivatives for non-small cell lung cancer
EP3443962B1 (en) Quinoline derivative for treating gastric cancer
WO2015185014A1 (zh) 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物
WO2016091165A1 (zh) 治疗非小细胞肺癌的喹啉衍生物
WO2018214925A1 (zh) 用于治疗结直肠癌的喹啉衍生物
WO2017118401A1 (zh) 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒
WO2020057536A1 (zh) 用于治疗脑肿瘤的喹啉衍生物
CN112533600B (zh) 用于治疗小细胞肺癌的喹啉衍生物
CN106999485B (zh) 抗肺鳞癌的喹啉衍生物
HK1238536B (zh) 抗肺鳞癌的喹啉衍生物
HK1238631B (zh) 抗非小细胞肺癌的喹啉衍生物
WO2019223672A1 (zh) 用于治疗非小细胞肺癌的喹啉衍生物
CN111110681A (zh) 喹啉衍生物联合卡培他滨在治疗肝癌的用途
HK40079036A (en) Quinoline derivative for treating non-small cell lung cancer
HK40046131A (en) Quinoline derivative used for treating small cell lung cancer
HK40046131B (en) Quinoline derivative used for treating small cell lung cancer
HK40080863A (en) Quinoline derivative for treating non-small cell lung cancer
HK1238631A1 (en) Quinoline derivative against non-small cell lung cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)